

CYSTIC FIBROSIS SCREEN
5520/LAB5520

QUICK REFERENCE

On August 03, 2022, the Cystic Fibrosis Screen (5520/LAB5520) became obsolete and made not orderable.

DETAILS

The reagent used by Allina Health Laboratory to perform the Cystic Fibrosis Screen assay has been discontinued by the manufacturer.

The suggested alternative test is the new Cystic Fibrosis (CF) profile, 32 mutations, DNA analysis assay (14545/LAB14545), referred to LabCorp.

Cystic Fibrosis (CF) profile, 32 mutations, DNA analysis-14545

Test info	Specimen	Performance	Clinical and Interpretive info	Billing	Tracking
Test name:		Cystic Fibrosis (CF) profile, 32 mutations, DNA analysis			
Test number:		14545			
Excellian order number:		LAB14545			
Abbreviation:		CFPLC			
Alternate names:		CF carrier			
Tests included:		Detection of 32 CF mutations: G85E; Δ I507; R553X; 711+1G>T; 3659delC; R117H; Δ F508; R560T; 1078delT; 3849+10kbC>T; V520F; R1162X; 1717-1G>A; 3876delA; R334W; G542X; W1282X; 1898+1G>A; 3905insT; R347P; S549N; N1303K; 2183AA>G; 2184delA; R347H; S549R; 394delT; 2789+5G>A; A455E; G551D; 621+1G>T; 3120+1G>A			
Useful for:		Help determine affected or carrier status for the 32 most common CF mutations			
Limitations:		This assay detects as many as 90% of cystic fibrosis carriers in the Caucasian population. Within other ethnic groups, there may be higher or lower detection efficiency. Includes the mutation profile currently recommended by the ACMG and the ACOG.			

QUESTIONS: Contact your Allina Health Laboratory account representative, or our Client Services department

Telephone: 612-863-4678 • 800-281-4379
centrallabclientservices@allina.com
www.allinahealth.org/allinahealthlaboratory